Hansoh Pharmaceutical Group Gestion
Gestion contrôle des critères 2/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Huijuan Zhong
Directeur général
CN¥14.8m
Rémunération totale
Pourcentage du salaire du PDG | 49.6% |
Durée du mandat du directeur général | 8.9yrs |
Propriété du PDG | n/a |
Durée moyenne d'occupation des postes de direction | 8.7yrs |
Durée moyenne du mandat des membres du conseil d'administration | 7.1yrs |
Mises à jour récentes de la gestion
Recent updates
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly
Nov 21Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?
Nov 04Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Analyse de la rémunération des PDG
Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
---|---|---|---|
Jun 30 2024 | n/a | n/a | CN¥5b |
Mar 31 2024 | n/a | n/a | CN¥4b |
Dec 31 2023 | CN¥15m | CN¥7m | CN¥3b |
Sep 30 2023 | n/a | n/a | CN¥3b |
Jun 30 2023 | n/a | n/a | CN¥3b |
Mar 31 2023 | n/a | n/a | CN¥3b |
Dec 31 2022 | CN¥11m | CN¥5m | CN¥3b |
Sep 30 2022 | n/a | n/a | CN¥3b |
Jun 30 2022 | n/a | n/a | CN¥3b |
Mar 31 2022 | n/a | n/a | CN¥3b |
Dec 31 2021 | CN¥16m | CN¥8m | CN¥3b |
Rémunération vs marché: La rémunération totale de Huijuan ($USD 2.04M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 906.94K ).
Rémunération et revenus: La rémunération de Huijuan a augmenté de plus de 20 % au cours de l'année écoulée.
PDG
Huijuan Zhong (63 yo)
8.9yrs
Titularisation
CN¥14,807,000
Compensation
Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...
Équipe de direction
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Chairlady | 8.9yrs | CN¥14.81m | pas de données | |
Executive Director | 8.7yrs | CN¥9.39m | 0.023% HK$ 25.3m | |
Executive Director | 8.9yrs | CN¥16.63m | 0.021% HK$ 22.8m | |
VP & CFO | no data | pas de données | pas de données | |
Chief of Science Officer | 2.6yrs | pas de données | pas de données | |
Senior Vice President | 15.7yrs | pas de données | pas de données | |
Chief Commercial Officer | no data | pas de données | pas de données | |
Joint Company Secretary & Senior VP | 6.3yrs | pas de données | pas de données | |
Joint Company Secretary | less than a year | pas de données | pas de données |
8.7yrs
Durée moyenne de l'emploi
54.5yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de 3692 est chevronnée et expérimentée (8.7 années d'ancienneté moyenne).
Membres du conseil d'administration
Nom | Position | Titularisation | Compensation | Propriété |
---|---|---|---|---|
Chairlady | 8.9yrs | CN¥14.81m | pas de données | |
Executive Director | 8.7yrs | CN¥9.39m | 0.023% HK$ 25.3m | |
Executive Director | 8.9yrs | CN¥16.63m | 0.021% HK$ 22.8m | |
Independent Non-Executive Director | 5.5yrs | CN¥360.00k | pas de données | |
Independent Non-Executive Director | 5.5yrs | CN¥360.00k | pas de données | |
Independent Non-Executive Director | 5.5yrs | CN¥360.00k | pas de données |
7.1yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de 3692 sont considérés comme expérimentés (ancienneté moyenne 7.1 ans).